Galenicum opens US subsidiary
Galenicum abre filial en Estados Unidos
Intel ID : 237220
| Synopsis |
|
Galenicum, a pharmaceutical company, entered the United States through the opening of its new subsidiary in Houston, as published on website PMFARMA on May 30, 2016, citing its CEO, Luis Alabern. Galenicum has entered the United States through US-based Zachary Sniderman, who will lead the project.
(content in spanish)
Galenicum, empresa farmacéutica, ha desembarcado en Estados Unidos con la apertura de una nueva filial en Houston, según ha publicado el portal PMFARMA el 30 de mayo de 2016, basándose en declaraciones de Luis Alabern, director general de la compañía. Galenicum ha entrado en el mercado estadounidense de la mano del estadounidense Zachary Sniderman, que será el encargado de estar al frente del proyecto. |
|
||||
| Intel ID | 237220 | |
| Value | ND | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Galenicum
(31 Dec 2017) |
Revenue: EUR 73,36m EBITDA: EUR 9,93m Net Debt: EUR 44,90m |
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography |  |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.